Amneal Pharmaceuticals (AMRX) Income from Continuing Operations (2017 - 2026)

Amneal Pharmaceuticals' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 78000000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 216.84% year-over-year to 78000000.0 in Q1 2026; TTM through Mar 2026 was 181315000.0, a 459.27% increase from a year earlier, with the FY2025 full-year figure at 127933000.0, up 273.17% from the prior year.
• Income from Continuing Operations rose to 78000000.0 in Q1 2026 per AMRX's latest filing, from 49573000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 78000000.0 in Q1 2026 and bottomed at 240081000.0 in Q2 2022.
• The 5-year median for Income from Continuing Operations is 11757000.0 (2024), against an average of 10086352.94.
• Biggest YoY gain for Income from Continuing Operations was 1147.41% in 2023; the steepest drop was 1504.68% in 2023.
• Year by year, Income from Continuing Operations stood at 5817000.0 in 2022, then tumbled by 1504.68% to 93344000.0 in 2023, then jumped by 77.78% to 20742000.0 in 2024, then soared by 339.0% to 49573000.0 in 2025, then soared by 57.34% to 78000000.0 in 2026.
• Per Business Quant, the three latest AMRX Income from Continuing Operations figures stand at 78000000.0 (Q1 2026), 49573000.0 (Q4 2025), and 18132000.0 (Q3 2025).